Bone is living tissue with a complex blood supply, and its ability to heal depends critically on adequate oxygen delivery. When bone is fractured, infected, or reconstructed surgically, the healing process can fail or stall when oxygen supply is inadequate. HBOT has an established role in certain bone healing situations and is FDA-cleared for one of them. Here’s a clear picture of what it helps, what it doesn’t, and what the evidence shows. It is part of a broader group of HBOT applications for chronic pain that are being studied in hyperbaric research.
Why Bone Healing Needs Oxygen
Bone regeneration is an oxygen-intensive process. Osteoblasts (bone-forming cells) require oxygen for collagen synthesis and mineralization. Angiogenesis, the growth of new blood vessels into the healing bone callus, depends on VEGF signaling that requires adequate oxygen gradients. Immune cells clearing infection or dead bone need high oxygen levels for their oxidative killing mechanisms.
When any of these processes is oxygen-limited, whether due to impaired circulation, radiation damage, infection, or extensive bone loss, healing slows or fails. HBOT addresses this by providing oxygen concentrations in tissue that substantially exceed what normal circulation can achieve.
Osteomyelitis: The Strongest Evidence
Chronic osteomyelitis, infection of bone, represents HBOT’s clearest bone healing indication. Infected bone is typically ischemic: bacteria, biofilm formation, and the destruction of the bone’s blood supply combine to create tissue that is profoundly hypoxic. This hypoxia impairs both immune clearance and antibiotic efficacy.
HBOT works in osteomyelitis through multiple mechanisms: direct toxicity to anaerobic bacteria, restoration of neutrophil oxidative killing capacity in ischemic tissue, improved antibiotic penetration (particularly aminoglycosides), and stimulation of angiogenesis to gradually rebuild the bone’s vascular supply. It is used as an adjunct following surgical debridement, not as a standalone treatment.
UHMS recognizes refractory osteomyelitis as an approved HBOT indication, and the evidence base, while not from large randomized trials, is consistent across multiple retrospective series and case studies. The HBOT and infections article covers the infection-specific mechanisms.
Osteoradionecrosis
When bone within a radiation field loses its blood supply and dies, osteoradionecrosis (ORN) results. The jaw is the most commonly affected site after head and neck cancer radiation, but ORN can also occur in ribs, clavicle, and pelvic bones. HBOT is a cornerstone of ORN management, both for treating established ORN and for preventing it before dental procedures in previously irradiated jaw tissue.
The standard protocol for jaw ORN involves 20 HBOT sessions before any surgical intervention and 10 sessions after, though variations exist based on severity. For preventing ORN before tooth extractions in irradiated fields, 20 sessions pre-operatively and 10 post-operatively is the standard protocol recommended by the UHMS. The broader radiation injury context is covered in the radiation damage article.
Fracture Healing
Standard uncomplicated fractures in healthy patients heal through a well-orchestrated biological process that doesn’t typically require HBOT. The evidence for HBOT as a routine fracture healing adjunct is not strong enough to support its use in normal fracture management.
Where HBOT has more rationale in fracture care is in specific challenging situations: non-union (fractures that fail to heal despite adequate treatment), fractures in diabetic patients with compromised vascularity, open fractures with extensive soft tissue damage, and fractures in previously irradiated bone. In these situations, the same impaired oxygen delivery that HBOT addresses in wound healing and osteomyelitis is present in the fracture healing process. Evidence in these specific fracture subgroups is limited but more plausible than for uncomplicated fractures.
Bone Graft Healing
Bone grafts, whether autologous (from the patient) or allograft (from donor bone), must establish new blood supply (revascularize) to integrate successfully. In compromised tissue beds, such as previously irradiated areas or poorly vascularized diabetic tissue, graft revascularization is impaired. HBOT has been used perioperatively to improve the tissue bed before graft placement and to support graft integration afterward.
Evidence is primarily case series and retrospective data. Controlled trials of HBOT for bone graft healing specifically are lacking, but the biological rationale is consistent with HBOT’s established mechanisms in compromised tissue healing.
Distraction Osteogenesis
Distraction osteogenesis is a surgical technique that gradually separates bone ends to stimulate new bone formation (used in limb lengthening and jaw reconstruction). The new bone that forms in the distraction gap requires robust vascularization to mineralize properly. Small studies have shown faster and more complete bone regeneration in distraction osteogenesis when HBOT is used as an adjunct, likely through enhanced angiogenesis in the forming bone callus. This is an intriguing application but remains research-stage rather than standard of care.
Factors That Affect HBOT Response in Bone Healing
Smoking significantly impairs HBOT’s angiogenic effects and is strongly associated with worse outcomes in bone healing HBOT applications. Smokers have substantially reduced benefit from HBOT for osteoradionecrosis and osteomyelitis compared to non-smokers. Diabetes, while not a contraindication, adds complexity: the same vascular impairment that makes diabetic patients need HBOT also reduces its absolute effectiveness. Aggressive diabetes management alongside HBOT improves outcomes.
The post-surgery recovery article and general recovery article provide broader context on optimizing HBOT outcomes across healing applications.
Hyperbaric Oxygen and Orthopedic Hardware
Some bone healing applications involve patients with orthopedic hardware: screws, plates, rods, and intramedullary nails from previous surgeries. A common question is whether this metal hardware is safe in the hyperbaric chamber. The answer is yes, for the vast majority of orthopedic implants. Standard orthopedic hardware is composed of titanium or stainless steel alloys that are not affected by the pressure changes in a hyperbaric chamber and are not ferromagnetic (unlike MRI, HBOT doesn’t create a magnetic field). Any implanted device should be disclosed to the hyperbaric physician before treatment, but orthopedic hardware is rarely a barrier.
The Special Challenge of Avascular Necrosis
Avascular necrosis (AVN or osteonecrosis) is a condition in which the blood supply to a bone segment is interrupted, leading to bone death. It commonly affects the femoral head (hip), humeral head (shoulder), and small bones of the wrist and foot. AVN can be caused by steroid use, alcohol use, trauma, radiation, and several other factors. HBOT has been studied as an intervention for early AVN before structural collapse occurs, with the hypothesis that improving oxygenation and stimulating angiogenesis might support bone survival and delay or prevent the need for joint replacement.
Evidence is limited to small studies, predominantly in femoral head AVN, with some showing benefit in early stages (before radiographic collapse) and less benefit in advanced stages. HBOT is not a standard AVN treatment, but it represents an area of ongoing interest as an option for early-stage disease when surgery is being deferred.
Bone Marrow Contribution to Healing
HBOT’s well-documented effect on stem cell mobilization from bone marrow (increasing circulating CD34+ cells) may have particular relevance to bone healing applications. Bone contains its own stem cell niche (osteoprogenitor cells) that contributes to repair. HBOT-stimulated growth factors including PDGF and TGF-beta support osteoblast differentiation and activity. Whether these mechanisms meaningfully accelerate bone repair in clinical practice beyond what good surgical technique and standard care provide remains an important research question.
Monitoring Bone Healing Response During HBOT
For patients receiving HBOT for osteomyelitis or osteoradionecrosis, monitoring bone healing response requires imaging at appropriate intervals. Plain radiographs, CT scans, and MRI each provide different information about bone healing progress: plain films show gross bone structure changes; CT shows cortical detail and sequestrum; MRI is sensitive to marrow changes and soft tissue. A baseline imaging study before starting HBOT, and follow-up imaging at the end of the treatment course and several months after, documents response and guides decisions about surgical intervention or additional sessions.
Clinical response measures, including pain levels, local inflammatory signs, wound healing progress, and inflammatory lab values (ESR, CRP), supplement imaging and are typically tracked throughout the treatment course. A response assessment framework agreed upon between the hyperbaric physician and the orthopedic or oral-maxillofacial surgeon ensures that treatment decisions are made on consistent, objective data rather than clinical impression alone.
Frequently Asked Questions
How many HBOT sessions are needed for osteomyelitis?
Protocols typically involve 40 to 60 sessions, used following surgical debridement and in conjunction with prolonged antibiotic therapy. The number of sessions depends on the extent and chronicity of the infection, the amount of bone involved, and the patient’s response to treatment.
Can HBOT heal a non-union fracture without surgery?
Unlikely for established non-unions. Non-unions typically require surgical intervention (fixation revision, bone grafting, or other procedures) to create the biological and mechanical environment for healing. HBOT may support healing after such surgery but is not a substitute for it in most cases.
Is HBOT covered by insurance for osteomyelitis?
HBOT for refractory osteomyelitis is an approved HBOT indication covered by Medicare and most commercial insurers when criteria are met (documentation of refractory infection despite adequate antibiotic therapy, use following appropriate surgery). Prior authorization is required. The insurance coverage guide covers the authorization process. The cost guide provides context if coverage is partial or denied.
What is "refractory" osteomyelitis?
Refractory osteomyelitis is bone infection that has failed to respond to adequate antibiotic therapy (typically a prolonged course) and surgical debridement. It’s characterized by persistent signs of infection despite appropriate treatment. This distinction is important for insurance purposes, as HBOT coverage for osteomyelitis generally requires documentation of treatment refractoriness.
References
- Bennett MH, et al.. “Hyperbaric oxygen therapy for promoting fracture healing and treating fracture non-union.” Cochrane Database of Systematic Reviews, 2012. DOI: 10.1002/14651858.CD004712.pub4
- Kawada S, et al.. “Hyperbaric oxygenation enhances bone formation and promotes osteoblastic differentiation.” PLoS ONE, 2013. DOI: 10.1371/journal.pone.0072603
- Shao JY, et al.. “Clinical study of HBOT for limb fracture healing.” Chinese clinical study, 2011.
- Hadanny A, et al.. “Hyperbaric oxygen therapy for the treatment of bone-related diseases.” PubMed Review, 2025. DOI: PMID 39940834
- Undersea and Hyperbaric Medical Society. “HBO Therapy Indications.” UHMS, 2024. DOI: uhms.org
- Mayo Clinic. “Hyperbaric oxygen therapy.” Mayo Clinic, 2024. DOI: mayoclinic.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
